VRTX Vertex Pharmaceuticals Inc
Company Analysis
Latest News
Vertex Reports VX-548 Hits Phase 3 Goal for Diabetic Nerve Pain
Vertex Pharmaceuticals said its pivotal Phase 3 study of VX-548, a selective NaV1.8 inhibitor, met its primary endpoint in patients with painful diabetic...
🔴 Vertex Pharmaceuticals is trading 5% down in pre-market with no clear company-specific catalyst identified
Vertex Pharmaceuticals is trading at $497.00, down -5.25%, in pre-market on October 22, 2026, with no clear company-specific announcement identified to explain...
🟢 Vertex Pharmaceuticals is trading 4.3% up in pre-market amid a reported Wall Street Zen upgrade
Vertex Pharmaceuticals is trading at $521.21 (+4.30%) in pre-market on October 19, with a reported Wall Street Zen upgrade a possible contributor. - Wall...
🔴 Vertex Pharmaceuticals is trading 4% down amid biotech-sector weakness
Vertex Pharmaceuticals is trading 4.02% lower at $486.60 on October 13, 2026; no clear company-specific announcement explaining the decline surfaced, while...
Vertex Kidney Drug Cuts Proteinuria 43%, Advancing Toward 2027 Approval
Vertex Pharmaceuticals reported positive Phase 2b results for inaxaplin, a treatment for APOL1-mediated kidney disease (AMKD). The drug reduced the urine...
Vertex Expands Beyond Cystic Fibrosis, Targets November Kidney Drug Approval
CEO Reshma Kewalramani detailed Vertex Pharmaceuticals' expansion beyond cystic fibrosis at the Morgan Stanley 24th Annual Global Healthcare Conference. The...
Vertex Pharmaceuticals Target Raised to $560, Citing Crinetics Acquisition
JPMorgan resumed coverage of Vertex Pharmaceuticals (VRTX) with an Overweight rating. The firm increased its price target for the stock from $515 to $560. The...
Vertex Closes $10 Billion Crinetics Deal, Targeting $5 Billion Revenue Peak
Vertex Pharmaceuticals finalized its acquisition of Crinetics Pharmaceuticals on September 1, 2026. The transaction carries a total equity value of...
Vertex Pharmaceuticals Appoints Jonathan Poole as New CFO, Effective January 2027
Vertex Pharmaceuticals announced the appointment of Jonathan Poole as its new Executive Vice President and Chief Financial Officer, effective January 1, 2027....
🟢 Vertex Pharmaceuticals rises 4.0% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
🔴 Vertex Pharmaceuticals is trading 6% down in after-hours trading — catalyst remains unconfirmed
Vertex Pharmaceuticals is trading 5.96% down now at $484.83 after no new company-specific announcement was identified for August 17, 2026; the catalyst remains...
Vertex clears antitrust hurdles for $10 billion Crinetics deal
Vertex Pharmaceuticals cleared major regulatory hurdles to acquire Crinetics Pharmaceuticals. The U.S. Hart-Scott-Rodino waiting period expired on August 12,...
Vertex Beats, Raises, and Rallies 12% in a Week — But Can New Drug Bets Justify the Price Tag?
Shares surged as Vertex Pharmaceuticals posted a second quarter that cleared Wall Street's bar on revenue and prompted the company to lift its full-year...
🟢 Vertex Pharmaceuticals is trading 6.8% up today after revenue beat and raised 2026 guidance
Vertex Pharmaceuticals is trading 6.8% up at $529.95 following continued positive investor response to its August 3 second-quarter report. - Revenue increased...
🟢 Vertex Pharmaceuticals is trading 5.8% up in pre-market after 12% revenue growth, higher 2026 guidance
Vertex Pharmaceuticals is trading +5.83% at $525.01 in pre-market as investors continued responding positively to its August 3 second-quarter report. -...
Vertex Pharmaceuticals' second quarter revenue of $3.33B beats estimates, driven by CF franchise and new product growth.
Vertex Pharmaceuticals reported second quarter 2026 revenue of $3.33 billion, up 12% year-over-year, beating analyst estimates. Non-GAAP diluted EPS was $4.73,...
Vertex Pharmaceuticals Inc Q2 2026 Earnings Preview: What Analysts Expect on August 03, 2026
Vertex Pharmaceuticals is expected to report Q2 2026 revenue of $3.23 billion and EPS of 4.30, while its current price of $477.10 sits significantly below the...
🔴 VRTX is trading 4.2% down today after announcing a $10B Crinetics acquisition
VRTX is trading 4.2% down at $500.27 as investors digest its planned $10 billion cash acquisition of Crinetics Pharmaceuticals. • The deal, partly funded with...
Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $85.00 Per Share
Vertex Pharmaceuticals has entered into a definitive agreement to acquire Crinetics Pharmaceuticals, Inc. in an all-cash transaction. Under the terms of the...
Vertex Pharmaceuticals to Acquire Crinetics for $10 Billion in Rare Disease Push
Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals for approximately $10 billion in equity value, paying $85 per share in cash. [2, 3, 4]...